ANGLE plc (ANPCY)
- Previous Close
2.3900 - Open
2.3900 - Bid 1.3500 x --
- Ask 3.9100 x --
- Day's Range
2.3900 - 2.3900 - 52 Week Range
1.1295 - 4.0000 - Volume
2 - Avg. Volume
464 - Market Cap (intraday)
62.379M - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9800 - Earnings Date Sep 5, 2024 - Sep 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
angleplc.com173
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ANPCY
Performance Overview: ANPCY
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANPCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANPCY
Valuation Measures
Market Cap
49.84M
Enterprise Value
34.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.41
Price/Book (mrq)
2.14
Enterprise Value/Revenue
12.57
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.07%
Return on Equity (ttm)
-69.68%
Revenue (ttm)
1.82M
Net Income Avi to Common (ttm)
-22.28M
Diluted EPS (ttm)
-0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
22.16M
Total Debt/Equity (mrq)
14.26%
Levered Free Cash Flow (ttm)
-11.26M
Company Insights: ANPCY
ANPCY does not have Company Insights